Novo Nordisk A/S (NYSE:NVO) Holdings Lifted by Somerville Kurt F

Somerville Kurt F increased its position in shares of Novo Nordisk A/S (NYSE:NVO - Free Report) by 88.7% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 16,923 shares of the company's stock after purchasing an additional 7,953 shares during the quarter. Somerville Kurt F's holdings in Novo Nordisk A/S were worth $1,175,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently added to or reduced their stakes in the business. Zevin Asset Management LLC boosted its holdings in shares of Novo Nordisk A/S by 39.5% in the 1st quarter. Zevin Asset Management LLC now owns 84,691 shares of the company's stock valued at $5,881,000 after buying an additional 23,983 shares during the period. Sustainable Growth Advisers LP lifted its holdings in Novo Nordisk A/S by 3.8% in the first quarter. Sustainable Growth Advisers LP now owns 5,543,246 shares of the company's stock worth $384,923,000 after acquiring an additional 202,443 shares during the last quarter. M. Kulyk & Associates LLC lifted its holdings in Novo Nordisk A/S by 1,970.9% in the first quarter. M. Kulyk & Associates LLC now owns 65,897 shares of the company's stock worth $4,576,000 after acquiring an additional 62,715 shares during the last quarter. Y Intercept Hong Kong Ltd boosted its stake in Novo Nordisk A/S by 98.1% in the first quarter. Y Intercept Hong Kong Ltd now owns 247,815 shares of the company's stock valued at $17,208,000 after acquiring an additional 122,734 shares during the period. Finally, Obermeyer Wealth Partners grew its holdings in shares of Novo Nordisk A/S by 4.7% during the first quarter. Obermeyer Wealth Partners now owns 136,174 shares of the company's stock valued at $9,456,000 after purchasing an additional 6,070 shares during the last quarter. Institutional investors and hedge funds own 11.54% of the company's stock.

Analysts Set New Price Targets

NVO has been the topic of several recent research reports. Wall Street Zen raised Novo Nordisk A/S from a "hold" rating to a "buy" rating in a report on Saturday, June 14th. BNP Paribas started coverage on Novo Nordisk A/S in a research note on Tuesday, April 15th. They issued an "underperform" rating on the stock. BMO Capital Markets reissued a "market perform" rating and set a $64.00 price target (down previously from $105.00) on shares of Novo Nordisk A/S in a report on Thursday, April 17th. Guggenheim cut shares of Novo Nordisk A/S from a "strong-buy" rating to a "hold" rating in a report on Thursday, April 17th. Finally, Dbs Bank lowered shares of Novo Nordisk A/S to a "sell" rating in a research note on Friday, April 25th. Two research analysts have rated the stock with a sell rating, five have given a hold rating, four have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the company has an average rating of "Hold" and an average price target of $112.00.

Novo Nordisk A/S Stock Performance

Shares of NVO traded up $0.71 during trading hours on Thursday, reaching $70.74. 10,157,270 shares of the company's stock traded hands, compared to its average volume of 7,044,014. Novo Nordisk A/S has a twelve month low of $57.00 and a twelve month high of $139.74. The business's fifty day simple moving average is $70.43 and its two-hundred day simple moving average is $73.97. The company has a debt-to-equity ratio of 0.70, a current ratio of 0.74 and a quick ratio of 0.56. The firm has a market capitalization of $315.84 billion, a price-to-earnings ratio of 20.93, a P/E/G ratio of 1.35 and a beta of 0.64.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last released its earnings results on Wednesday, May 7th. The company reported $0.92 EPS for the quarter, meeting the consensus estimate of $0.92. Novo Nordisk A/S had a net margin of 34.52% and a return on equity of 80.94%. The firm had revenue of $11.87 billion for the quarter. Analysts predict that Novo Nordisk A/S will post 3.84 earnings per share for the current year.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.